Narrative-Based Sexual Medicine: Clinical Vignettes and PDE5 Inhibitor Management in Real-World ED

Two of four authors work for Viatris — a PDE5i manufacturer — yet COI is listed as "not listed"

Journal: The Aging Male | Published: 2026-04-02 | Type: Narrative Review | PMID: 41928386 Authors: Andrea Sansone (University, Dept. Systems Medicine); Raffaella Mantegazza (Viatris Italia S.r.l.); Shivani Ohri Vignesh (Mylan Pharmaceuticals / Viatris, India); Emmanuele A. Jannini (University, Dept. Biomedicine and Prevention) Funding/COI: Not listed — despite two authors employed by Viatris, a pharmaceutical company that manufactures PDE5 inhibitors including orodispersible sildenafil, the specific formulation this paper promotes

Summary

This paper presents fictional clinical vignettes about ED management to argue that "narrative medicine" is an underused tool in sexual health, and that personalized PDE5i prescribing — including orodispersible film formulations — improves patient outcomes. There are no patients, no data, and no statistics. Two of the four authors are employees of Viatris, the company that manufactures the drug class and specific formulation the paper advocates for, and this conflict goes undisclosed in the journal's COI field.

Claims

• Narrative-based medicine (NBM) is "particularly well suited" to sexual medicine because ED is multifactorial
• ED should be framed as a "sentinel symptom of systemic health" per "Systems Sexology" theory
• "Symptom-pill" approaches are inadequate; multidimensional, personalized care is needed
• Orodispersible film PDE5i formulations "may enhance discretion, acceptability, and adherence"
• Italian SIAMS guidelines provide the normative framework for the vignettes

No quantitative findings. No effect sizes. No sample sizes. No p-values. These are illustrative stories, not data.

Study Quality

This is a narrative review built around fictional clinical vignettes — the lowest tier of evidence short of a personal opinion piece. There is no systematic search methodology, no inclusion/exclusion criteria, no patient population, and no outcomes measured. The paper uses Italian SIAMS guidelines as a "normative framework," meaning the vignettes are constructed to illustrate guidelines rather than to test them. "Narrative review" in this context means: the authors chose which literature to cite, with no obligation to represent the full evidence base.

The framing as clinical vignettes gives the paper a veneer of real-world applicability while insulating it from any empirical scrutiny. You cannot critique the methodology of a fictional story.

Red Flags

• Undisclosed industry authorship: Raffaella Mantegazza is listed as affiliated with Viatris Italia S.r.l.; Shivani Ohri Vignesh with Mylan Pharmaceuticals / Viatris. Viatris manufactures generic PDE5 inhibitors. The journal's COI field reads "Not listed." This is not a disclosure failure by the researchers — it is a publication failure by the journal
• The paper promotes a specific Viatris product: Orodispersible sildenafil film is a Viatris product. The abstract's conclusion specifically calls it out as enhancing "discretion, acceptability, and adherence" — with no citation supporting these claims in the abstract
• No data: Clinical vignettes are explicitly fictional ("realistic" is the word used). There is nothing to replicate, audit, or challenge
• "Systems Sexology" is a theoretical framework, not validated clinical science — it is presented here without critical examination
• The journal (The Aging Male) has historically published pharma-adjacent content in this space — this paper fits a pattern

Strengths

• The framing of ED as systemic rather than purely mechanical has legitimate support in the broader literature
• Narrative medicine as a concept has real academic backing in chronic disease management
• Calling out the inadequacy of "symptom-pill" prescribing is a valid clinical concern

Verdict

This paper is industry promotional content in academic clothing. Two pharma employees co-authoring an uncited narrative review that specifically advocates for their employer's drug formulation, published without conflict-of-interest disclosure, is not science journalism — it is advertising. The underlying concept (personalized ED care beats one-size-fits-all prescribing) has merit, but this paper contributes nothing to the evidence base. It should be read, if at all, as a case study in how pharmaceutical companies use narrative review format to launder product advocacy into peer-reviewed literature.